A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)

• Status: NOT_YET_RECRUITING
• Trial end date: 2037-03-13

Summary

Researchers are looking for new ways to treat relapsed or refractory, diffuse large B-cell lymphoma (R/R DLBCL). Relapsed means the cancer came back after treatment. Refractory means the number of cancer cells in the body did not go down or the cancer did not go away after treatment. Researchers want to learn if MK-1045, an immunotherapy, can treat R/R DLBCL when given with zilovertamab vedotin (ZV), a type of targeted therapy.

The goals of this trial are to learn:

• About the safety of MK-1045 and ZV and if participants tolerate them together. To tolerate these drugs together means that participants will receive the trial medicines unless they need to stop them due to health problems
• About the number of participants whose cancer responds (gets smaller or goes away) to treatment with MK-1045 and ZV
• If participants who receive MK-1045 and ZV live longer without the cancer growing or spreading compared to participants who receive standard treatments

• Phase: PHASE2

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: Bendamustine Hydrochloride; Granulocyte Colony-Stimulating Factor; Lenalidomide; polatuzumab vedotin; Rituximab; tafasitamab